Meta-analysis of placebo remission rate for patients with moderately to severely active Crohn's disease

被引：0
|
作者：
Loftus, Edward, Jr.
Wu, Eric
Johnson, Scott
Chao, Jingdong
Mulani, Parvez
机构：
[1] Mayo Clin, Coll Med, Div Gastroenterol & Hepatol, Rochester, MN USA
[2] Anal Grp Inc, Boston, MA USA
[3] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2008年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
970
引用
收藏
页码：S380 / S381
页数：2
相关论文
共 50 条
  • [1] Sustained Remission with Adalimumab Therapy in Japanese Patients with Moderately to Severely Active Crohn's Disease
    Hibi, Toshifumi
    Watanabe, Mamoru
    Kumar, Ashish
    Camez, Anne
    Lomax, Kathleen
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S463 - S463
  • [2] A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease
    Su, CY
    Lichtenstein, GR
    Krok, K
    Brensinger, CM
    Lewis, JD
    GASTROENTEROLOGY, 2004, 126 (05) : 1257 - 1269
  • [3] Unemployment and disability in patients with moderately to severely active Crohn's disease
    Feagan, BG
    Bala, M
    Yan, S
    Olson, A
    Hanauer, S
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2005, 39 (05) : 390 - 395
  • [4] Time to effect of biologics and small molecules for patients with moderately to severely active luminal Crohn's disease - a systematic review and network meta-analysis
    Attauabi, M.
    Steenholdt, C.
    Burisch, J.
    Gubatan, J.
    Nielsen, O. H.
    Seidelin, J. B.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I124 - I126
  • [5] Achievement of steroid-free remission in patients with moderately to severely active Crohn's Disease during treatment with risankizumab
    Schreiber, S. W.
    Cross, R.
    Panaccione, R.
    D'Haens, G.
    Bossuyt, P.
    Colombel, J. F.
    Louis, E.
    Dubinsky, M.
    Kligys, K.
    Neimark, E.
    Song, A.
    Zambrano, J.
    Cheng, E.
    Ferrante, M.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I125 - I126
  • [6] ACHIEVEMENT OF STEROID-FREE REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE DURING TREATMENT WITH RISANKIZUMAB
    Schreiber, Stefan
    Cross, Raymond K.
    Panaccione, Remo
    D'Haens, Geert
    Bossuyt, Peter
    Colombel, Jean Frederic
    Louis, Edouard
    Dubinsky, Marla
    Kligys, Kristina
    Neimark, Ezequiel
    Song, Alexandra P.
    Zambrano, Javier A.
    Cheng, Erica
    Ferrante, Marc
    GASTROENTEROLOGY, 2022, 162 (07) : S966 - S966
  • [7] Network meta-analysis: Comparative onset of early effect of biologics and small molecules in moderately to severely active luminal Crohn's disease
    Attauabi, Mohamed
    Steenholdt, Casper
    Poulsen, Anja
    Gubatan, John
    Burisch, Johan
    Nielsen, Ole Haagen
    Seidelin, Jakob Benedict
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (02) : 124 - 143
  • [8] MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
    Loftus, Edward
    Pollack, Paul
    Hunter, Theresa
    Shan, Mingyang
    Chan, Lai-Shan
    Deckard, Deanilee
    Cross, Raymond
    GASTROENTEROLOGY, 2022, 162 (03) : S15 - S15
  • [9] Upadacitinib improves symptomatic responses in patients with moderately to severely active Crohn's disease
    Blumenstein, I.
    Torres, J.
    Ma, C.
    Lindsay, J. O.
    Ungaro, R.
    Thin, L.
    Lacerda, A. P.
    Anyanwu, S. I.
    Garrison, A.
    Ford, S.
    Louis, E.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : II000 - I1001
  • [10] MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
    Loftus, Edward
    Pollack, Paul
    Hunter, Theresa
    Shan, Mingyang
    Chan, Lai-Shan
    Deckard, Deanilee
    Cross, Raymond
    INFLAMMATORY BOWEL DISEASES, 2022, 28 : S15 - S15
12345